newsfilter
← Latest News
Business Wire·

U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease

If approved, ENTYVIO would be the only gut-focused treatment for patients two years and older with moderately to severely active ulcerative colitis (UC) or Crohn's disease Potential for ENTYVIO to address